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We  analyzed  the  effects  of  different  administration  routes  and  application  times  of  the  BCG-Moreau
strain  on airway  and  lung  inﬂammation  and  remodeling  in  a  murine  model  of  allergic  asthma.  BALB/c
mice  (n  =  168)  were  divided  into  two  groups.  The  ﬁrst  group  received  BCG-Moreau  strain  while  the  second
group  received  saline  using  the  same  protocol.  BCG  or saline  were  intradermally  or intranasally  injected
one or two  months  before  the induction  of  asthma.  Mice  were  further  sensitized  and  challenged  withirway remodeling
osinophilia
irway resistance
ovalbumin  or received  saline.  Twenty-four  hours  after  the  last  challenge,  BCG  prevented  the  triggering  of
pro-inﬂammatory  cytokines,  probably  by  increasing  Foxp3  and  interleukin  (IL)-10,  modulating  eosinophil
inﬁltration and  collagen  ﬁber  deposition,  thus  reducing  airway  hyperresponsiveness.  In conclusion,  BCG-
Moreau prevented  lung  remodeling  in  the  present  model  of allergic  asthma,  regardless  of administration
route  and  time  of  vaccination.  These  beneﬁcial  effects  may  be  related  to  the  increase  in  regulatory  T  cells
and  to  IL-10  production  in tandem  with  decreased  Th2  cytokines  (IL-4,  IL-5,  and  IL-13).. Introduction
Asthma is a chronic inﬂammatory disease affecting the air-
ays and lung parenchyma (Bateman et al., 2008), associated with
emodeling characterized by the following ultrastructural changes:
ubepithelial ﬁbrosis, mucous metaplasia, airway wall thickening,
mooth muscle cell hypertrophy and hyperplasia, myoﬁbroblast
yperplasia, vascular proliferation, and extracellular matrix abnor-
alities (Al-Muhsen et al., 2011). These changes accelerate decline
n lung function (Holgate, 2008) despite treatment with cortico-
teroids. Since lung remodeling is usually related to established
nﬂammation, it may  be hypothesized that early treatment with
mmunoregulatory agents could prevent damage.
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Recent studies have demonstrated the Bacillus Calmette–Guérin
(BCG) vaccine to be effective at reducing inﬂammation and hyper-
responsiveness in animal models (Lagranderie et al., 2008) and
in humans with asthma (Choi and Koh, 2002, 2003; Cohon et al.,
2007). However, the effectiveness of this treatment seems to
be affected by aspects of vaccine delivery: experimental stud-
ies report better control of the inﬂammatory process of asthma
with intranasal administration compared to the intradermal route
(Choi et al., 2007; Erb et al., 1998), even though the latter is
more commonly used in humans (Sarinho et al., 2010; Shirtcliffe
et al., 2004). Furthermore, there is controversy regarding the best
time of BCG administration before induction of allergy (Erb et al.,
1998; Nahori et al., 2001; Ozeki et al., 2011). Additionally, a strain-
dependent effect of BCG cannot be ruled out. In this line, the Moreau
strain, which is widely used for tuberculosis control in Brazil
(Benevolo-de-Andrade et al., 2005), has been observed to induce
an adaptive immunity while increasing cytokines from T helper 1
(Th1) and regulatory T cells (Treg) (Wu  et al., 2007), suggesting
that this vaccine could be a potential tool for prevention of allergic
asthma.
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Based on the aforementioned, we used a murine model of
llergic asthma to analyze the effects of different routes of admin-
stration and application times of the BCG-Moreau strain on
ulmonary inﬂammation, remodeling process, and lung function.
oreover, possible mechanisms of action were investigated.
. Materials and methods
This study was approved by the Ethics Committee of the Carlos
hagas Filho Institute of Biophysics, Health Sciences Center, Federal
niversity of Rio de Janeiro, Brazil (CEUA-CCS, IBCCF 019).
.1. Animal preparation
A total of 168 newly weaned male BALB/c mice (10–15 g) were
andomly divided into two groups. The ﬁrst group (n = 84) received
5 L of a solution of 106 UFC lyophilized BCG Moreau strain resus-
ended in saline while the second group (n = 84) received saline.
CG or saline were intradermally (n = 42) or intranasally (n = 42)
njected one or two months before the induction of allergic asthma.
These groups were further randomized into two other groups.
n the ovalbumin group (OVA), mice were immunized using an
djuvant-free protocol with intraperitoneal injection of ovalbumin
10 g in 0.1 mL  sterile saline) on each of seven alternate days.
orty days after the beginning of sensitization, 20 g of OVA in
0 L sterile saline were intratracheally instilled. This procedure
as performed three times at 3-day intervals. The control group
C) received saline using the same protocol.
Eighty-four animals were used for analysis of lung mechan-
cs and histology, and a second group of 84 animals was used for
nalysis of airway responsiveness and bronchoalveolar lavage ﬂuid
BALF). The BCG Moreau vaccine was donated by the Ataulpho de
aiva Foundation, Brazil.
.2. Assessment of lung mechanics
Twenty-four hours after the last challenge, mice were
edated (diazepam 1 mg  i.p.), anesthetized (thiopental sodium
0 mg/kg i.p.), tracheotomized, paralyzed (vecuronium bromide,
.005 mg/kg i.v.), and mechanically ventilated with the following
ettings: respiratory frequency 100 breaths/min, tidal volume (VT)
.2 mL,  and fraction of inspired oxygen (FiO2) 0.21. The anterior
hest wall was surgically removed and a positive end-expiratory
ressure (PEEP) of 2 cmH2O was applied, and the lung mechan-
cs were computed. At the end of the experiment, the lungs were
repared for histology and molecular biology. Airﬂow, volume and
racheal pressure (Ptr) were measured (Hsia et al., 2010). In an
pen chest preparation, Ptr reﬂects transpulmonary pressure (PL).
ung static elastance and airway resistance were computed by the
nd-inﬂation occlusion method (Bates et al., 1985) using the ANA-
AT data analysis software (RHT-InfoData, Inc., Montreal, Quebec,
anada).
.3. Airway responsiveness
Twenty-four hours after the last challenge, airway respon-
iveness was measured. Increasing doses of methacholine (Sigma
hemical Co., Saint Louis, MI,  USA) (100, 300, 1000, 3000, and
0,000 g/kg) were administered via a silastic catheter placed in
he jugular vein. Data were stored at 30 s, 1, 3, and 5 min  after
gonist injection. Shortly after each intravenous infusion of metha-
holine, the maximal increase in Ptr was reached, and the respective
irﬂow was measured at this moment (Antunes et al., 2009). Respi-
atory system resistance (R) was obtained using the equation of
otion of the respiratory system: Ptr(t) = E·V(t) + R·V′(t), where (t)
s time.& Neurobiology 189 (2013) 614– 623 615
2.4. Lung histology
The right lung was removed, ﬁxed in 4% buffered formalde-
hyde, parafﬁn-embedded, and cut into 4 m-thick slices, which
were stained with hematoxylin and eosin (Vetec Química Fina,
Rio de Janeiro, Brazil). Fraction area of collapsed and normal lung
areas were determined by the point-counting technique at a mag-
niﬁcation of 200× across 10 random, non-coincident microscopic
ﬁelds (Hsia et al., 2010). Points falling on collapsed or normal pul-
monary areas were counted and divided by the total number of
points in each microscopic ﬁeld. Polymorphonuclear (PMN) and
mononuclear (MN) cells and lung tissue were evaluated at 1000×
magniﬁcation. Points falling on PMN  and MN cells were counted
and divided by the total number of points falling on lung tissue in
each microscopic ﬁeld.
Airway bronchoconstriction index was determined by counting
the points falling on the airway lumen and those falling on airway
smooth muscle and on the epithelium, at a magniﬁcation of 400×.
The number of intercepts (NI) of the lines with the epithelial basal
membrane is proportional to the airway perimeter, and the number
of points (NP) falling on the airway lumen is proportional to airway
area; thus, the magnitude of bronchoconstriction was  computed as
CI = NI/NP½. Measurements were performed in ﬁve airways from
each animal at 400× magniﬁcation.
Collagen ﬁbers (Picrosirius-polarization method) (Montes,
1996) were quantiﬁed in alveolar septa and airways with the aid of
a digital analysis system and speciﬁc software (Image-Pro®Plus 5.1
for Windows® Media Cybernetics – Silver Spring, MD,  USA) under
200× magniﬁcation. The area occupied by ﬁbers was determined
by digital densitometric recognition. To avoid any bias due to alve-
olar collapse, the areas occupied by collagen ﬁbers in each alveolar
septum were divided by the area. The results were expressed as
the percentage of collagen ﬁber content per tissue area (%). Col-
lagen ﬁber content was  quantiﬁed in the whole circumference of
the two  largest, transversally cut airways present in the sections.
Results were expressed as the area of collagen ﬁbers divided by the
perimeter of the basement membrane (m2/m).
2.5. Immunohistochemistry
Right lungs were ﬁxed in 4% paraformaldehyde and embedded
in parafﬁn for immunohistochemistry using monoclonal antibody
against -smooth muscle actin (Dako, Carpenteria, CA, USA) at a
1:500 dilution. The analysis was performed on the slides stained
for -smooth muscle actin applying the point-counting technique.
Using a 121-point grid, we calculated the volume proportion of
smooth-muscle-speciﬁc actin in terminal bronchioles and alveolar
ducts as the relation between the number of points falling on actin-
stained and non-stained tissue. Measurements were done at 400×
magniﬁcation in each slide (Hsia et al., 2010).
2.6. Transmission electron microscopy
Three 2 mm × 2 mm × 2 mm slices were cut from three different
segments of the left lung and ﬁxed [2.5% glutaraldehyde and phos-
phate buffer 0.1 M (pH 7.4)] for electron microscopy (JEOL 1010
Transmission Electron Microscope, Tokyo, Japan) analysis. For each
electron microscopy image (20/animal), the following structural
changes were analyzed: (a) shedding of surface epithelium, (b) air-
way  edema, (c) eosinophil inﬁltration, (d) neutrophil inﬁltration, (e)
disorganization of ciliated epithelial cells, (f) subepithelial ﬁbrosis,
(g) elastic ﬁber fragmentation, (h) smooth muscle hypertrophy, (i)
myoﬁbroblast hyperplasia, and (j) mucous cell hyperplasia. Patho-
logic ﬁndings were graded according to a 5-point semi-quantitative
severity-based scoring system as: 0 = normal lung parenchyma,
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 = changes in 1–25%, 2 = changes in 26–50%, 3 = changes in 51–75%,
nd 4 = changes in 76–100% of examined tissue (Jeffery et al., 1992).
Histological analysis was performed by a blinded pathologist.
.7. Bronchoalveolar lavage ﬂuid (BALF)
Total leukocyte count in BALF was performed in a Neubauer
hamber with optical microscopy after diluting the samples in
ürk solution. Differential leukocyte counts were performed in
ytospin smears stained by the May–Grünwald–Giemsa method.
he amount of interleukin (IL)-4, IL-5, IL-10, IL-12, IL-13, IL-17,
nterferon (IFN)-  and transforming growth factor (TGF)- in the
ell-free BALF was evaluated by ELISA in accordance with the man-
facturer’s instructions (Duo Set, R&D Systems, Minneapolis, USA).
.8. Foxp3 expression
Quantitative real-time reverse transcription (RT) polymerase
hain reaction (PCR) was performed to measure the relative lev-
ls of expression of Foxp3 genes in lung tissue (Yang et al.,
009). Total RNA was extracted from the frozen tissues using the
V Total RNA Isolation System (Promega, Rio de Janeiro, Brazil)
ccording to manufacturer instructions. RNA concentrations were
easured in a Nanodrop® ND-1000 spectrophotometer. First-
trand cDNA was synthesized from total RNA using the GoTaq®
-Step RT-qPCR System (Promega, Rio de Janeiro, Brazil), accord-
ng to manufacturer recommendations. Relative mRNA levels were
easured with a SYBR green detection system using a Master-
ycler ep realplex2 S (Eppendorf, São Paulo, Brazil). All samples
ere measured in triplicate. The relative amount of expression
f each gene was calculated as the ratio of studied gene to a
ontrol gene (acidic ribosomal phosphoprotein P0 [36B4]) and
xpressed as fold changes relative to C or OVA groups. The follow-
ng PCR primer was used: 5′-GAGCCAGAAGAGTTTCTCAAGC-3′ and
′-GCTACGATGCAGCAAGAGC-3′.
.9. Statistical analysis
Two-way ANOVA followed by Tukey’s test was used to compare
ll data considering route of administration and moment of injec-
ion as the study factors. A correlation between mechanical and
istological data was analyzed using Spearman’s correlation test.
 p value less than 0.05 was considered signiﬁcant. All tests were
erformed in GraphPad Prism 4.0 (GraphPad Software, San Diego,
A).
. Results
The BCG-Moreau vaccine effectively reduced remodeling and
ung inﬂammation, with positive effects on lung mechanics and
orphometry, with no difference between administration route or
ime.
.1. Remodeling
Collagen ﬁber content in the airway and lung parenchyma
Fig. 1A), as well as the amount of -smooth muscle actin in the
erminal bronchiole and alveolar ducts (Fig. 1B) were higher in
he SAL-OVA group compared to its respective control (SAL-C).
CG-Moreau therapy, regardless of route and moment of adminis-
ration, prevented these alterations (Fig. 1A–C). Since no signiﬁcant
ifference on lung mechanics and histology were observed in
ice treated with saline (data not shown), intradermally and
ntranasally treated animals were pooled in a single group.
In the SAL-OVA group, electron microscopy evidenced sev-
ral ultra-structural changes in terminal bronchioles that are & Neurobiology 189 (2013) 614– 623
characteristic of asthma: shedding of surface epithelium, elas-
tic ﬁber fragmentation, subepithelial ﬁbrosis, disorganization of
ciliated cells, myoﬁbroblast hyperplasia, and smooth muscle
hypertrophy. These ultrastructural changes were minimized by
administration of BCG-Moreau before the asthma protocol (Table 1
and Fig. 2).
3.2. Lung inﬂammation
The inﬂammatory process was evaluated by counting total and
differential cells in lung tissue and BALF (Fig. 3). The number of poly-
morphonuclear cells in lung tissue and of eosinophils in BALF was
signiﬁcantly higher in the SAL-OVA group compared to the other
groups (Fig. 3). The administration of BCG-Moreau intradermally
or intranasally, one or two months before asthma induction, atten-
uated the allergen-induced inﬂammatory process (Fig. 3), with no
statistical differences among BCG-treated groups.
3.3. Lung mechanics
Airway hyperresponsiveness, airway resistance (Raw), and lung
static elastance (Est, L) were higher in SAL-OVA when compared to
SAL-C (Fig. 4). BCG minimized these mechanical changes, with no
statistical differences among BCG-treated groups (Fig. 4).
3.4. Lung histology and morphometry
The fraction area of alveolar collapse and the bronchoconstric-
tion index were signiﬁcantly higher in SAL-OVA than in SAL-C,
and the administration of BCG-Moreau prevented these alterations
(Fig. 5). Considering all groups together, lung static elastance was
well correlated with the fraction area of alveolar collapse, while air-
way  resistance was  correlated with the bronchoconstriction index
(p < 0.05).
3.5. Mechanisms of action of BCG-Moreau vaccine on lung
inﬂammation and remodeling
In order to investigate the possible mechanisms of action of
the BCG-Moreau vaccine in the proposed allergic asthma model,
cytokines with Th1 (IFN-, IL-12), Th2 (IL-4, IL-5 IL-13), Th17 (Th17)
and Treg (IL-10), TGF- proﬁle and the mRNA expression of Foxp3
(Fig. 7) were measured. BCG led to IL-10 and Foxp3 increase, while
reducing IL-4, IL-5, and IL-13 in OVA group (Figs. 6 and 7). No sig-
niﬁcant changes were observed in the other mediators (data not
shown).
4. Discussion
In the present study, intranasal and intradermal administra-
tion of BCG-Moreau vaccine, one or two  months before asthma
induction, minimized the inﬂammatory process. More importantly,
BCG-Moreau vaccine prevented airway and lung parenchyma
remodeling – as evidenced by the reduction of both collagen ﬁber
content and percentage of smooth muscle-speciﬁc actin in terminal
bronchioles and alveolar ducts, maintenance of airway epithelium
integrity and by the decrease in subepithelial ﬁbrosis, fragmenta-
tion of elastic ﬁbers, and hyperplasia of myoﬁbroblasts. Prevention
of ultrastructural changes by BCG-Moreau treatment resulted in
improved pulmonary function when compared to saline-treated
OVA-challenged animals, as assessed by lung mechanics and airway
hyperresponsiveness. Furthermore, these beneﬁcial effects were
associated with an increase in IL-10 and Foxp3, as well as with a
reduction in Th2 cytokines.
BALB/c mice were chosen because of their greater ability to
develop airway hyperresponsiveness and eosinophilia after chronic
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Fig. 1. Collagen ﬁber content in airway and lung parenchyma (panel A) and fraction area of smooth muscle speciﬁc actin in the terminal bronchioles and alveolar ducts (panel
B)  in SAL and BCG groups treated intradermally (i.d.) or intranasally (i.n.), one or two months before sensitization and challenge with ovalbumin (OVA). Control (C) group
r group
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ceceived saline using the same protocol. Values are means ± SEM of 6 mice in each 
panel  C). *Signiﬁcantly different from SAL-C (p < 0.05). †Signiﬁcantly different from
ensitizations and challenges with ovalbumin (Antunes et al.,
009). The present protocol was able to reproduce some aspects
f human chronic asthma, such as airway hyperresponsiveness,
osinophilia, smooth muscle hypertrophy, and increased basement
embrane thickness (Mestas and Hughes, 2004; Xisto et al., 2005).
n this study, the BCG protocol was begun as soon as the mice
ere weaned, since BCG is usually administered at a very young
ge (World Health Organization, 2004). Experimental (Erb et al.,
998; Hopfenspirger and Agrawal, 2002; Major et al., 2002; Shen
t al., 2008; Tukenmez et al., 1999) and clinical studies (Aaby et al.,
000; Alm et al., 1997; Bager et al., 2003; Choi and Koh, 2002) are
ontroversial concerning the best time for BCG administration. Erb. Photomicrographs of the airways were taken at an original magniﬁcation of 400×
VA group (p < 0.05).
et al. found that the action of this vaccine decreased over time,
and that the best results were achieved between two  and four
weeks before induction of the allergic process (Erb et al., 1998). Con-
versely, Nahori et al. reported BCG effects lasting more than 8 weeks
(Nahori et al., 2001), while Ozeki et al. observed a high amount of
BCG mainly in the spleen up to 20 weeks after administration (Ozeki
et al., 2011). Based on the aforementioned, we administered BCG-
Moreau one or two months before asthma induction. Moreover,
previous studies have also suggested an inﬂuence of BCG adminis-
tration route on the vaccine’s effectiveness (Choi et al., 2007; Erb
et al., 1998; Hopfenspirger and Agrawal, 2002). In this context, Erb
et al. argue that BCG should be administered directly into the lung
618 C.d.S. Samary et al. / Respiratory Physiology & Neurobiology 189 (2013) 614– 623
Table  1
Ultrastructural changes of airways.
Ultrastructural parameters SAL BCG
C OVA* 1 month 2 months
i.d.-OVA† i.n.-OVA† i.d.-OVA† i.n.-OVA†
Shedding of surface epithelium 0 (0–0) 3 (2.5–3.0) 1 (0.5–1.5) 1 (0.5–1.0) 1 (1.0–2.0) 1 (0.5–1.0)
Airway edema 0 (0–0) 3 (2.5–3.5) 1 (1.0–1.5) 1 (0–1.0) 0 (0–1.0) 0 (0–1.0)
Eosinophils 0 (0–0) 3 (2.5–4.0) 1 (0.5–1.5) 1 (1–2) 1 (0.5–2.0) 1 (0.5–1.0)
Neutrophils 0 (0–0) 2 (1–2) 0 (0–1.0) 1 (0–1.0) 1 (0–1) 0 (0–1.0)
Disorganization of ciliated epithelial cells 0 (0–0) 3 (2.5–3.5) 0 (0–1.0) 0 (0–1.0) 0 (0–1.0) 0 (0–1.0)
Subepithelial ﬁbrosis 0 (0–0) 3 (3.0–4.0) 1 (0–1.0) 1 (0–1.0) 1 (0–1.0) 1 (0.5–1.0)
Smooth muscle hypertrophy 0 (0–0) 3 (2.5–4.0) 1 (1.0–1.5) 1 (0.5–1.0) 1 (1.0–1.5) 1 (0.5–1.5)
Myoﬁbroblast hyperplasia 0 (0–0) 4 (3.0–4.0) 1 (0.5–1.5) 1 (1.0–1.5) 1 (0–1.0) 1 (0.5–1.5)
Elastic ﬁber fragmentation 0 (0–0) 2 (1.5–2.5) 0 (0–0.5) 0 (0–1.0) 0 (0–1.0) 0 (0–0.5)
Mucous cell hyperplasia 0 (0–0) 3 (2.0–3.5) 1 (0–1.0) 1 (0.5–1.0) 1 (0.5–1.5) 1 (0.5–1.5)
Semiquantitative analysis of the ultrastructural changes in the airway. Mice received saline (SAL) or Bacillus Calmette–Guérin (BCG), intradermally (i.d.) or intranasally
(i.n.),  one or two  months before sensitization and challenge with ovalbumin (OVA). The control (C) group received saline using the same protocol. Values are median (25th
percentile–75th percentile) of 5 animals per group. Pathologic ﬁndings were graded according to a 5-point semi-quantitative severity-based scoring system: 0 = normal lung
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* Signiﬁcantly different from SAL-C (p < 0.05).
† Signiﬁcantly different from SAL-OVA group (p < 0.05).
o promote better effects (Erb et al., 1998). However, clinical tri-
ls have employed the intradermal route for BCG administration
Sarinho et al., 2010; Shirtcliffe et al., 2004). We  therefore compared
he intradermal and intranasal routes. Erb et al. observed that the
oute of BCG administration inﬂuenced airway eosinophilia, with
ntranasal infection being superior to intraperitoneal or subcuta-
eous infection in its ability to reduce airway eosinophilia (Erb
t al., 1998). Conversely, our study demonstrated that the admin-
stration of BCG-Moreau intradermally or intranasally, one or two
onths before asthma induction, attenuated the allergen-induced
nﬂammatory process, with no statistical differences between BCG-
reated groups. Regarding the BCG vaccine dose, 106 CFU was used
ecause it has been associated with a better immune response
Nahori et al., 2001; Yang et al., 2002).
ig. 2. Electron microscopy of the ultrastructural changes in the airway. Mice received s
i.n.),  one or two  months before animals were sensitized and challenged with ovalbulmin 
ill,  ciliated cells; BM,  basement membrane.ed tissue.
Previous genomic analyses of BCG vaccines demonstrate that
there is genetic variability among the strains, leading to controver-
sies regarding BCG efﬁcacy (Davids et al., 2006; Wu  et al., 2007).
However, the present results suggest that the protective efﬁcacy
of BCG-Moreau remains unaltered. According to recent molecular
studies (Brosch et al., 2007), BCG-Moreau, which has been used in
Brazil for vaccine production since the 1920s (Berredo-Pinho et al.,
2011), belongs to the group of “older” strains that are closer to the
attenuated strain originally derived by Calmette and Guérin. The
BCG-Moreau strain is used in 5% of the BCG vaccines produced in the
world (Benevolo-de-Andrade et al., 2005). Allied to its availability
(Hayashi et al., 2009) and meaningful role in vaccine preparations,
the BCG-Moreau strain has immunogenic effects, as shown herein.
In this line, this is the ﬁrst study to date describing the ability of
aline (SAL) or Bacillus Calmette–Guérin (BCG), intradermally (i.d.) or intranasally
(OVA). Control (C) group received saline using the same protocol. MC, Mucous cells;
C.d.S. Samary et al. / Respiratory Physiology & Neurobiology 189 (2013) 614– 623 619
Fig. 3. Tissue cellularity – MN,  mononuclear cells; PMN, polymorphonuclear cells (panel A); total cells, mononuclear cells, eosinophils and neutrophils in bronchoalveolar
lavage  ﬂuid (BALF) (panel B). Mice were treated with saline (SAL) or Bacillus Calmette–Guérin (BCG), intradermally (i.d.) or intranasally (i.n.), one or two months before
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eans  ± SEM of 6 mice in each group. *Signiﬁcantly different from SAL-C (p < 0.05).
he BCG-Moreau strain to reduce inﬂammation and remodeling in
xperimental asthma.
Studies have shown that the correlation between number of
osinophils and pulmonary airway reactivity has a critical impact
n disease severity and number of exacerbations (Bousquet et al.,
990). An asthma model using eosinophil-deﬁcient genetically
odiﬁed PHIL mice demonstrated the essential role of eosinophils
n airway hyperresponsiveness and pulmonary mucus accumula-
ion (Lee et al., 2004). Eosinophils may  also contribute to airway
emodeling, In this line, total ablation of eosinophil lineage reduced
sthma-induced airway remodeling, as demonstrated by a decrease
n peribronchiolar collagen deposition and fewer smooth muscle-
peciﬁc actin positive cells (Humbles et al., 2004). Moreover,
osinophils produce a multitude of ﬁbrogenic factors, such asng the same protocol. Values are mean ± SEM of 6 mice in each group. Values are
iﬁcantly different from SAL-OVA group (p < 0.05).
TGF-, IL-11, IL-17, and IL-25 (Hamid and Tulic, 2009). In fact,
eosinophils are the major source of TGF- in asthmatic airways
(Minshall et al., 1997; Ohno et al., 1996), and they are an impor-
tant source of numerous cytokines (e.g. IL-4, IL-5, IL-10, IL-13)
that may  inﬂuence the innate and adaptive immune responses
associated with asthma (Hamid and Tulic, 2009). Eosinophils also
produce lipid mediators such as cysteinyl leukotrienes (Weller
et al., 1983) and PGD2 (Luna-Gomes et al., 2011), which con-
tribute to the recruitment of innate and adaptive immunity cells,
edema formation, and bronchoconstriction (Barnes, 2011). Thus, an
immunomodulatory therapy that reduces eosinophil recruitment
may  prevent inﬂammation and remodeling in allergic airways.
BCG treatment reduced both mononuclear and PMN  accumula-
tion in the airways, but its most prominent effect seems to be on
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Fig. 4. Airway responsiveness induced by increasing methacholine doses (100, 300, 1000, 3000, and 10,000 g/kg) (panel A); airway resistance (Raw) (panel B); lung static
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nd  challenge with ovalbumin (OVA). Control (C) group received saline using the 
rom  SAL-C (p < 0.05). †Signiﬁcantly different from SAL-OVA group (p < 0.05).
osinophils, which were markedly reduced in BALF. This reduction
ay  be associated with the decrease in IL-4, IL-5, and IL-13 (Hamid
nd Tulic, 2009).
IL-13 produced by T cells, eosinophils, or innate helper cells
Hamid and Tulic, 2009; Holgate, 2012) has a central role in airway
yperresponsiveness development (Grunig et al., 1998; Wills-Karp
t al., 1998). BCG treatment completely abrogated IL-13 production
n lungs of antigen-challenged mice, suggesting a causative rela-
ion with inhibition of lung parenchyma remodeling. Meanwhile,
CG treatment had no clear effect on TGF- production in OVA-
hallenged mice. This lack of a clear-cut effect of BCG may  reﬂect
he somewhat controversial role of TGF- in asthma. While TGF-
romotes goblet-cell and smooth muscle hyperplasia and subep-
thelial ﬁbrosis, aggravating airway hyperresponsiveness (Halwani
t al., 2011), it may  also limit airway remodeling by inhibiting tissue
amage through inhibition of T and inﬂammatory cells (Holgate,
012).
The asthma model used in this study promoted a stereotypical
h2 cytokine proﬁle with increase in cytokines related to airway
nd lung parenchyma inﬂammation and remodeling processes.
CG prevented asthma-associated alterations through modiﬁca-
ion of the adaptive immune response, which led to reduced levels
f IL-4, IL-5, and IL-13 after antigen challenge. Bilenki et al. showed
hat BCG may  reduce allergic inﬂammation of the airways through
nduction of a Th1-skewed response by mycobacterium activated
endritic cells. Transfer of dendritic cells from BCG-infected mice
o mice sensitized with ragweed extract induced higher IFN-
nd IL-12 while inhibiting IL-4, 5, -9, and -13 allergen-induced
roduction by spleen and draining lymph node cell cultures, indi-
ating a Th1-dominated immune response (Bilenki et al., 2010).
everal experimental studies in Th2-mediated diseases, including), intradermally (i.d.) or intranasally (i.n.), one or two months before sensitization
protocol. Values are means ± SEM of 6 mice in each group. *Signiﬁcantly different
asthma, have shown an inhibition of Th2 compared to Th1 stim-
ulus (Erb et al., 1998; Koh et al., 2001; Lagranderie et al., 2010;
Tukenmez et al., 1999). However, we did not ﬁnd an increase in Th1
response-associated cytokines (IFN- and IL-12), thus indicating
that a Th1-dependent inhibition of the allergic response is unlikely
in our model. Such differences may  arise from variations in study
design, administration route of BCG, the speciﬁc BCG strain used,
or the time elapsed between BCG administration and allergic chal-
lenge. We  strived to reproduce as closely as possible the effects
of BCG vaccination as done in public health campaigns around the
world and particularly in Brazil.
Regulatory T cells (Tregs) also seem to counteract Th2 response
in allergic subjects (Holgate, 2012); thus, induction of Tregs may
represent an additional potential mechanism of BCG protection in
asthma (Ahrens et al., 2009). Regardless of route or time of admin-
istration, BCG promoted an increase in Foxp3 gene expression in
lung, suggesting an increase in Tregs. Furthermore, this increase in
Foxp3 expression was independent of OVA sensitizations and chal-
lenges, as observed in the control groups. Increase in Foxp3 was
paralleled by an increase in IL-10 production after antigen chal-
lenge; this suggests that BCG may  reduce asthma inﬂammation
by favoring accumulation of IL-10-producing Tregs in lungs. IL-10
(Bilenki et al., 2010; Gao et al., 2012) and Tregs (Gao et al., 2012)
have also been shown to play a central role in BCG-induced decrease
in allergic inﬂammation.
Asthma is a chronic inﬂammatory disease in which an exacer-
bated Th2 response is a central component that leads to changes in
airway responsiveness and structure, as well as function impair-
ment (Hamid and Tulic, 2009). The focus of this study was to
investigate if BCG-Moreau vaccination would have a positive
impact on asthmatic airway function due to its immunomodulatory
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Fig. 5. Bronchoconstriction index (panel A) and fraction area of alveolar collapse (panel C). Mice received saline (SAL) or Bacillus Calmette–Guérin (BCG), intradermally (i.d.)
or  intranasally (i.n.), one or two months before sensitization and challenge with ovalbumin (OVA). Control (C) group received saline using the same protocol. Values are
means  ± SEM of 6 mice in each group. Representative photomicrographs of airways and lung parenchyma taken from an original magniﬁcation of 400× (panel B) and of 200×
(panel  D), respectively. *Signiﬁcantly different from SAL-C (p < 0.05). †Signiﬁcantly different from SAL-OVA group (p < 0.05).
Fig. 6. Interleukin (IL)-4, IL-5, IL-13 and IL-10 in bronchoalveolar lavage ﬂuid (BALF). Mice received saline (SAL) or Bacillus Calmette–Guérin (BCG), intradermally (i.d.)
or  intranasally (i.n.), one or two months before sensitization and challenge with ovalbumin (OVA). Control (C) group received saline using the same protocol. Values are
means  ± SEM of 6 mice in each group. *Signiﬁcantly different from SAL-C (p < 0.05). †Signiﬁcantly different from SAL-OVA group (p < 0.05).
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Fig. 7. Foxp3 mRNA expression in mice receiving saline (SAL) or Bacillus
Calmette–Guérin (BCG), intradermally (i.d.) or intranasally (i.n.), one or two  months
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Signiﬁcantly different from SAL-OVA (p < 0.05).
ffects. BCG-Moreau vaccination completely abrogated allergen-
nduced increases in airway resistance and elastance due its effect
f reducing bronchoconstriction and alveolar collapse, respectively.
oreover, it signiﬁcantly inhibited the airway hyperresponsive-
ess that is a hallmark of asthma. Improvement of airway function
as paralleled by inhibition of airway remodeling. The number
f -smooth muscle actin-positive myoﬁbroblasts was reduced in
ung tissue in BCG-OVA compared to SAL-OVA group, which may
e associated with the observed reduction in collagen deposition
nd subepithelial ﬁbrosis.
The strengths of this paper are the use of BCG-Moreau, a strain
idely used in children vaccination against tuberculosis in Brazil,
nd the modulation of lung remodeling. We  believe that these
trengths sufﬁciently counterbalance limitations such as the use
f only one mouse strain (precluding extrapolation of the results to
ther strains) and the fact that a prophylactic approach was tested
making the results inapplicable to therapeutic management).
The present study has limitations that need to be addressed: (1)
t has been described that the presence of viable organisms and
ranulomas in the lungs needs to be observed in order to charac-
erize BCG immunization. However, this was not observed in our
tudy, probably due analysis at a later time point, more than 60 days
Shaler et al., 2011). Thus, further studies should be performed ear-
ier, following BCG administration, to establish the granulomatous
nﬂammation; (2) we hypothesized that the beneﬁts we  observed
ere associated with increased Treg cells or IL-10. However, for
he study to be truly mechanistic, we should have demonstrated
hat the BCG vaccine could no longer protect against OVA-induced
sthma in the absence of Tregs or IL-10. Further studies are there-
ore warranted to address this point.
. Conclusion
In conclusion, in the present murine model of allergic asthma,
he BCG-Moreau strain prevented airway and lung parenchyma
emodeling, regardless of administration route and time of vac-
ination. These beneﬁcial effects may  be related to an increase in
he number of Treg cells and in the production of IL-10 in tandem
ith a decrease in Th2 (IL-4, IL-5, and IL-13) cytokines.unding
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